News & Updates

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024 by

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

Infertile women may benefit from oil-based contrast during HSG

01 Aug 2024

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024 by

In the treatment of genitourinary syndrome of menopause (GSM), the nonhormone alternative vaginal hyaluronic acid is equally efficacious as the treatment standard vaginal oestrogen, while being well-tolerated, as shown in a pilot study.

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024 by

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024 by

In the 3-year updated analysis of the phase III TOPAZ-1 study, the combination of durvalumab and gemcitabine-cisplatin (GC) chemotherapy continues to deliver an overall survival (OS) benefit in individuals with biliary tract cancer (BTC).

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

A more selective risk-based approach to an enoxaparin thromboprophylaxis protocol appears to reduce the incidence of wound hematomas without increasing the rates of postpartum venous thromboembolism (VTE), as shown in a retrospective study.

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

Personalized faricimab dosing shows durable efficacy in nAMD

30 Jul 2024 by

A treat-and-extend personalized treatment with faricimab based on disease activity results in sustained gains in vision or anatomic outcomes through 2 years in patients with neovascular age-related macular degeneration (nAMD), reports a study. Moreover, nearly four in five (80 percent) patients have achieved extended dosing intervals of 12 weeks or more.

Personalized faricimab dosing shows durable efficacy in nAMD

30 Jul 2024

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

30 Jul 2024 by

The addition of dostarlimab to a carboplatin-paclitaxel (CP) chemotherapy regimen confers an overall survival (OS) benefit in women with primary advanced or recurrent endometrial cancer (EC), according to the second interim analysis of the ENGOT-EN6/GOG-3031/RUBY trial part 1.

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

30 Jul 2024

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

29 Jul 2024

The use of oral corticosteroids for more than 90 days among individuals with atopic dermatitis (AD) appears to be associated with a slight increase in the risk of adverse events (AEs), according to a study.

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

29 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Infertile women may benefit from oil-based contrast during HSG

Infertile women may benefit from oil-based contrast during HSG

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Is it unsafe to use GLP-1 RAs in early pregnancy?

Is it unsafe to use GLP-1 RAs in early pregnancy?

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

Personalized faricimab dosing shows durable efficacy in nAMD

Personalized faricimab dosing shows durable efficacy in nAMD

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

RUBY update: Dostarlimab strengthens spot in the endometrial cancer treatment arena

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis